Epidemiology of hepatocellular carcinoma in Japan

Journal of Gastroenterology

Volumn 44, Issue SUPPL. 19, 2009, Pages 102-107

  Umemura, Takeji ^a   Ichijo, Tetsuya ^a   Yoshizawa, Kaname ^a   Tanaka, Eiji ^a   Kiyosawa, Kendo ^b  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGANO RED CROSS HOSPITAL   (Japan)

Author keywords

HBV; HCC; HCV; Interferon; Nonalcoholic steatohepatitis (NASH)

Indexed keywords

ANTIVIRUS AGENT; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; INTERFERON;

AGE; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; DIABETES MELLITUS; EARLY DIAGNOSIS; FATTY LIVER; GENDER; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS C; HUMAN; JAPAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MONOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; VIROLOGY;

AGE FACTORS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; JAPAN; LIVER NEOPLASMS; PREVALENCE; RISK FACTORS; SEX FACTORS;

EID: 58849166878     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2251-0     Document Type: Article

References (17)

1. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, et al. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. Hepatol Res 2007;37:676-691.
2. Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, Tanaka E. Hepatocellular carcinoma: Recent trends in Japan. Gastroenterology 2004;127:S17-S26.
3. Umemura T, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. Hepatol Res 2007;37(suppl 2):S95-S100.
4. Japan LCSGi. Survey and follow-up study of primary liver cancer in Japan. Report 11. Kanzo 1995;36:208-218.
5. Japan LCSGi. Survey and follow-up study of primary liver cancer in Japan. Report 12. Kanzo 1997;38:317-330.
6. Japan LCSGi. Survey and follow-up study of primary liver cancer in Japan. Report 13. Kanzo 1999;40:288-300.
7. Japan LCSGi. Survey and follow-up study of primary liver cancer in Japan. Report 14. Kanzo 2000;41:799-811.
8. Japan LCSGi. Survey and follow-up study of primary liver cancer in Japan. Report 15. Kanzo 2003;44:157-175.
9. Ikai I, Arii S, Ichida T, Okita K, Omata M, Kojiro M, Takayasu K, et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol Res 2005;32:163-172.
10. Orito E, Sugauchi F, Tanaka Y, Ichida T, Sata M, Tanaka E, Okanoue T, et al. Differences of hepatocellular carcinoma patients with hepatitis B virus genotypes of Ba, Bj or C in Japan. Intervirology 2005;48:239-245.
11. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, Kanda T, et al. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003;37:19-26.
12. Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, Iijima A, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998;27:1394-1402.
13. Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, Maeda Y, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:94-99.
14. Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, Tsubota A, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999;29:1124-1130.
15. Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, Ishibashi H, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut 2004;53:425-430.
16. Okanoue T, Minami M, Makiyama A, Sumida Y, Yasui K, Itoh Y. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Clin Gastroenterol Hepatol 2005;3:S89-S91.
17. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: A prospective study. Ann Intern Med 2007;146:649-656.